Latest Information

Neutrophil-to-Lymphocyte Ratio May Be Associated With mRCC Outcomes

April 26, 2012

Two recent studies have reported on the possible utility of assessing pre-treatment neutrophil-to-lymphocyte ratio (NLR) as a prognostic factor in mRCC.

Tandutinib Not Effective For mRCC

April 26, 2012

A small phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases (FLT3), has concluded that the novel agent has no clinical activity and excessive toxicity, and should not be developed further for mRCC.

Low Recurrence And Cancer Death Rates Associated With Kidney Cancer Subtype

March 31, 2012

Patients with papillary renal cell carcinoma, the second most common kidney cancer subtype, face a low risk of tumour recurrence and cancer-related death after surgery.

Experimental Treatment May Be More Effective At Slowing Advanced Kidney Cancer Than Sorafenib.

Bloomberg News (5/20, Langreth) reports, Pfizer announced that results of a late-stage trial "showed that its experimental drug axitinib was more effective in treating advanced kidney cancer than Bayer AG's Nexavar [sorafenib]." According to a summary of the study released in advance of the American Society of Clinical Oncology's annual meeting, among the "723 patients with advanced kidney cancer," those who received "axitinib lived a median of 6.7 months before their tumors progressed, compared with 4.7 months for patients who received Nexavar." Pfizer said the findings will be presented at the ASCO meeting on June 6.

Filed Under: Uncategorized